2021
DOI: 10.1016/j.biopha.2020.111103
|View full text |Cite
|
Sign up to set email alerts
|

Nanomedicines: Redefining traditional medicine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
52
0
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 86 publications
(54 citation statements)
references
References 137 publications
0
52
0
2
Order By: Relevance
“…Moreover, the incidence of these two kinds of hematological malignancies is increasing year by year, which undoubtedly poses a serious threat to human health and life safety. The occurrence and development of hematological malignancies are very rapid and complex, which is a complex process of the interaction between internal genetic factors (38)(39)(40)(41)(42)(43)(44), molecular signal transduction (45,46), metabolic factors (47)(48)(49), immune factors (50)(51)(52)(53)(54)(55), and tumor microenvironment (41,(56)(57)(58)(59). Although current chemotherapy can prolong the survival time of tumor patients (60,61), the prognosis and economic burden are still difficult problems in clinical work.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, the incidence of these two kinds of hematological malignancies is increasing year by year, which undoubtedly poses a serious threat to human health and life safety. The occurrence and development of hematological malignancies are very rapid and complex, which is a complex process of the interaction between internal genetic factors (38)(39)(40)(41)(42)(43)(44), molecular signal transduction (45,46), metabolic factors (47)(48)(49), immune factors (50)(51)(52)(53)(54)(55), and tumor microenvironment (41,(56)(57)(58)(59). Although current chemotherapy can prolong the survival time of tumor patients (60,61), the prognosis and economic burden are still difficult problems in clinical work.…”
Section: Discussionmentioning
confidence: 99%
“…MBP-426 ® of Mebiopharm Co., Ltd. (Tokyo, Japan) is an oxaliplatin-encapsulated transferrin-conjugated N-glutaryl phosphatidylethanolamineliposome and is indicated for gastric, oesophageal and gastro-oesophageal adenocarcinoma. The phase I clinical trial (NCT00355888) of MBP-426 ® was completed [7], with phase IIa/b starting (NCT00964080) for characterization of the safety profile in combination with leucovorin and fluorouracil. Mebiopharm Co., Ltd. has also developed other products including MBP-Y003, MBP-Y004, and MBP-Y005 in preclinical stages which are transferrin-conjugated liposomes loaded with methotrexate, docetaxel, and gemcitabine, respectively [73].…”
Section: Lipid-based Nanoparticles For Drug Deliverymentioning
confidence: 99%
“…Although four commercialized liposomes loading doxorubicin were already launched into the market successfully, ThermoDox ® is a new product with advanced characteristics, that showed a 5-fold release in doxorubicin concentration at the tumor site when compared to Doxil ® [74]. Phase III clinical trials of ThermoDox ® in combination with standardized radiofrequency ablation (NCT02112656) have been completed [7,74].…”
Section: Lipid-based Nanoparticles For Drug Deliverymentioning
confidence: 99%
See 2 more Smart Citations